EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C Coombs, Lori Leslie, Paul M Barr, Jennifer R Brown und 19 weitere

Clinical Lymphoma Myeloma and Leukemia · 2023-07 · 23 (7) · 515-526

DOI: 10.1016/j.clml.2023.03.010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-07. Verfasst von Mazyar Shadman und 30 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutch Cancer Center and University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings. MATERIALS AND METHODS: Using deidentified electronic medical records from the CLL Collaborative Study of Real-World Evidence, premature treatment discontinuation was assessed among FCR, BR, BTKi-based, and BCL-2-based regimen cohorts. RESULTS: Of 1364 1L patients (initiated in 1997-2021), 190/13.9% received FCR (23.7% discontinued prematurely); 255/18.7% received BR (34.5% discontinued prematurely); 473/34.7% received BTKi-based regimens, of whom 28.1% discontinued prematurely; and 43/3.2% received venetoclax-based regimens, of whom 16.3% discontinued prematurely (venetoclax monotherapy: 7/0.5%, of whom 42.9% discontinued; VG/VR: 36/2.6%, of whom 11.1% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 25/13.2%; BR: 36/14.1%; BTKi-based regimens: 75/15.9%) and disease progression (venetoclax-based: 3/7.0%). Of 626 2L patients, 20/3.2% received FCR (50.0% discontinued); 62/9.9% received BR (35.5% discontinued); 303/48.4% received BTKi-based regimens, of whom 38.0% discontinued; and 73/11.7% received venetoclax-based regimens, of whom 30.1% discontinued (venetoclax monotherapy: 27/4.3%, of whom 29.6% discontinued; VG/VR: 43/6.9%, of whom 27.9% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 6/30.0%; BR: 11/17.7%; BTKi-based regimens: 60/19.8%; venetoclax-based: 6/8.2%). CONCLUSION: The findings of this study highlight the continued need for tolerable therapies in CLL, with finite therapy offering a better tolerated option for patients who are newly diagnosed or relapsed/refractory to prior treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHumansBridged Bicyclo Compounds, HeterocyclicSulfonamidesDisease ProgressionAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Adverse eventsChemoimmunotherapyChemotherapyDisease progressionTargeted agents

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Fred Hutch Cancer Center and University of Washington, Seattle, WA.
  • AbbVie, Inc., North Chicago, IL. Electronic address: beenish.manzoor@abbvie.com.
  • AbbVie, Inc., North Chicago, IL.
  • The Cancer Center at Lowell General Hospital, Lowell, MA.
  • Weill Cornell Medicine, New York, NY.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Förderung

  • AbbVie

Zitieren

APA

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., …, & Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515-526. https://doi.org/10.1016/j.clml.2023.03.010

Vancouver

Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, et al. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia. 2023;23(7):515-526. doi:10.1016/j.clml.2023.03.010

BibTeX
@article{Shadman2023,
  author = {Shadman, Mazyar and Manzoor, Beenish S and Sail, Kavita and Tuncer, Hande H and Allan, John N and Ujjani, Chaitra and Emechebe, Nnadozie and Kamalakar, Rajesh and Coombs, Catherine C and Leslie, Lori and Barr, Paul M and Brown, Jennifer R and Eyre, Toby A and Rampotas, Alexandros and Schuh, Anna and Lamanna, Nicole and Skarbnik, Alan and Roeker, Lindsey E and Bannerji, Rajat and Eichhorst, Barbara and Fleury, Isabelle and Davids, Matthew S and Alhasani, Hasan and Jiang, Dingfeng and Hill, Brian T and Schuster, Stephen J and Brander, Danielle M and Pivneva, Irina and Burne, Rebecca and Guerin, Annie and Mato, Anthony R},
  title = {Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2023},
  volume = {23},
  number = {7},
  pages = {515--526},
  doi = {10.1016/j.clml.2023.03.010}
}
Kostenlos starten →